"TCT 2025: Elixir Medical’s arterial implant drops coronary events by nearly 50%" was originally created and published by ...
A new drug-eluting balloon can perform just as well as the standard treatment for patients with coronary in-stent restenosis ...
A bioadaptor implant that actively adapts to vessel physiology was linked to lower target lesion failure and target vessel ...
Follow-up over 10 years may show different patterns, and experts predict DCBs will likely be useful in certain populations.
New study results from a large international all-comer population of percutaneous coronary intervention (PCI) candidates ...
News-Medical.Net on MSN
Sirolimus-eluting balloon emerges as a safe and effective option for coronary in-stent restenosis
A new drug-eluting balloon can perform just as well as the standard treatment for patients with coronary in-stent restenosis ...
Cordis, a global leader in interventional cardiovascular technology, today announced the groundbreaking results from the ...
In separate treatment trials, one for de novo coronary lesions and the other for in-stent restenosis, a sirolimus-eluting ...
New study results from a large international all-comer population of percutaneous coronary intervention (PCI) candidates ...
2don MSN
Studies confirm that drug-coated balloons can replace stents – even in larger coronary arteries
In the treatment of larger narrowed blood vessels, drug-coated balloon catheters have been shown to deliver lasting and ...
USA: A new drug-eluting balloon (DEB) may offer a safer and equally effective alternative to conventional metallic stents for ...
The REC-CAGEFREE I trial1 by Chao Gao and colleagues describes the results of a multicentre trial in which a paclitaxel drug-coated balloon (DCB) did not reach expected non-inferiority compared with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback